Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
MOMA Therapeutics
Eli Lilly and Company
Masaryk Memorial Cancer Institute
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Beijing Biotech
Fred Hutchinson Cancer Center
Exscientia AI Limited
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
Memorial Sloan Kettering Cancer Center
858 Therapeutics, Inc.
Institut de Cancérologie de Lorraine
City of Hope Medical Center
National Cancer Institute (NCI)
Orano Med LLC
University of Southern California
Filamon LTD
Atavistik Bio, Inc
PMV Pharmaceuticals, Inc
AstraZeneca
University of California, Davis
OHSU Knight Cancer Institute
University of Michigan Rogel Cancer Center
Alterome Therapeutics, Inc.
Rutgers, The State University of New Jersey
UMC Utrecht
Aveni Foundation
Monte Rosa Therapeutics, Inc
Psyence Australia Pty Ltd
ViroMissile, Inc.